Drug Profile
BAY 1003803
Alternative Names: BAY-1003803Latest Information Update: 28 Nov 2019
Price :
$50
*
At a glance
- Originator Bayer
- Class Anti-inflammatories; Antipsoriatics; Skin disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Psoriasis
Most Recent Events
- 28 Nov 2019 No recent reports of development identified for phase-I development in Psoriasis in Germany (Topical, Cream)
- 28 Nov 2019 No recent reports of development identified for phase-I development in Psoriasis in Germany (Topical, Ointment)
- 28 Sep 2017 Bayer terminates a phase I trial for Psoriasis (In volunteers) in Germany (Topical) (NCT02936492)